<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have characterised the <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel blocking properties of a new non-<z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SB 201823-A, in cultures of rat sensory neurones </plain></SENT>
<SENT sid="1" pm="."><plain>The IC50 for SB 201823-A against total <z:chebi fb="0" ids="29108">Ca2+</z:chebi> current in sensory neurones was 4.9 microM </plain></SENT>
<SENT sid="2" pm="."><plain>SB 201823-A showed little selectivity for sub-types of neuronal <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel but was selective for <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channels over <z:chebi fb="1" ids="29101">Na+</z:chebi> and K+ channels </plain></SENT>
<SENT sid="3" pm="."><plain>Efficacy against other types of <z:chebi fb="36" ids="36916">cation</z:chebi> channel such as <z:chebi fb="4" ids="48705">agonist</z:chebi> gated channels was not assessed </plain></SENT>
<SENT sid="4" pm="."><plain>SB 201823-A was neuroprotective in vivo when administered post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in one focal and one global model of neuronal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In the rat photothrombotic focal lesion model, SB 201823-A administered i.p </plain></SENT>
<SENT sid="6" pm="."><plain>10 min post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> resulted in a dramatic reduction in lesion volume </plain></SENT>
<SENT sid="7" pm="."><plain>In the gerbil bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> global model, SB 201823-A dosed i.p </plain></SENT>
<SENT sid="8" pm="."><plain>30 min post-occlusion resulted in both histological and functional improvements when compared to vehicle treated animals </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggest that such novel neuronal <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonists</z:chebi> may have potential in ameliorating both the pathological and functional consequences of <z:hpo ids='HP_0001297'>stroke</z:hpo> in man </plain></SENT>
</text></document>